RESCRIPTOR Drug Patent Profile

Which patents cover Rescriptor, and when can generic versions of Rescriptor launch?

Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Additional details are available on the delavirdine mesylate profile page.

Summary for RESCRIPTOR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	7
Patent Applications:	4,316
Drug Prices:	Drug price information for RESCRIPTOR
DailyMed Link:	RESCRIPTOR at DailyMed

See drug prices for RESCRIPTOR

Recent Clinical Trials for RESCRIPTOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Diego	Phase 2/Phase 3
National Institutes of Health (NIH)	Phase 2/Phase 3
National Institute of Mental Health (NIMH)	Phase 2/Phase 3

See all RESCRIPTOR clinical trials

US Patents and Regulatory Information for RESCRIPTOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997		DISCN	Yes	No
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999		DISCN	Yes	No

Expired US Patents for RESCRIPTOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	5,563,142
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	6,177,101
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	6,177,101
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	5,563,142

International Patents for RESCRIPTOR

See the table below for patents covering RESCRIPTOR around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	200163
Australia	4213499
Slovenia	1083885
Japan	H07110852
Canada	2071529	COMPOSES DIAROMATIQUES SUBSTITUES CONTRE LE SIDA (DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS)
Denmark	0507861

RESCRIPTOR Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of the Prescription Drugs Market: Implications for RESCRIPTOR and Similar Drugs

Introduction

The global prescription drugs market is on a significant growth trajectory, driven by several key factors. Understanding these market dynamics is crucial for pharmaceutical companies, including those developing drugs like RESCRIPTOR, to navigate and capitalize on the opportunities within this sector.

Market Size and Growth

The global prescription drugs market was valued at approximately USD 1,162.61 billion in 2023 and is projected to reach USD 2,151.63 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.1% during the forecast period of 2024 to 2032[3][4].

Drivers of Market Growth

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, respiratory disorders, and cancer is a major driver of the prescription drugs market. These conditions often require long-term medication regimens, thereby sustaining a high demand for prescription drugs[1].

Growing Aging Population

The global aging population is another significant factor fueling the demand for prescription medications. As people age, they are more likely to develop chronic conditions that require pharmaceutical interventions, contributing to the market's growth[1].

Advances in Medical Research and Technology

Continuous advances in medical research and technology lead to the discovery of new drug candidates and treatment approaches. This innovation is a key driver, enabling the development of more effective and targeted therapies[4].

Regional Analysis

North America

North America dominates the global prescription drugs market, accounting for a significant share due to the high prevalence of chronic diseases, high healthcare expenditure, robust R&D activities, and the presence of major pharmaceutical companies. The U.S. market, in particular, is expected to grow substantially, driven by the approval of orphan drugs and other advanced pharmaceuticals[3][4].

Europe

Europe holds the second-largest share in the global market, driven by increased demand for advanced prescription products and the launch of efficient prescription drugs, including orphan drugs. The introduction of generic drugs also contributes to the region's market growth[3].

Asia Pacific

The Asia Pacific region is projected to register a higher CAGR during the forecast period, driven by new product launches, a large potential patient population, and growing awareness of chronic and serious disorders. This region's market growth is further fueled by increasing healthcare expenditure[3][4].

Distribution Channels

Online Pharmacies

The online pharmacies segment is anticipated to grow at the highest CAGR, driven by the ease of refilling prescription medications and the convenience of acquiring drugs from home. This trend is particularly beneficial for patients with chronic conditions who require regular medication[3].

Market Restraints

High Pricing of Innovative and Specialty Medications

One of the significant restraints on the prescription drugs market is the high pricing of innovative and specialty medications. This can limit access to these drugs, especially in regions with lower healthcare expenditure[4].

Intellectual Property Challenges

Intellectual property disputes and challenges can hinder the market growth by delaying the approval and launch of new drugs. These issues can also affect the profitability of pharmaceutical companies[4].

Key Players and Competitive Landscape

Companies like Novartis AG and Pfizer, Inc. are leading players in the global prescription drugs market. These companies maintain their position through a strong and diversified product portfolio, continuous innovation, and robust R&D activities[3][4].

Impact of Regulatory Frameworks

Regulatory frameworks play a crucial role in the prescription drugs market. For instance, the FDA's accelerated approval process allows for faster approval of drugs based on surrogate endpoints, but it also requires postmarketing confirmatory studies to ensure the long-term safety and efficacy of these drugs. Effective oversight by regulatory bodies is essential to maintain public trust and ensure the quality of prescription medications[5].

Financial Trajectory for Pharmaceutical Companies

The financial trajectory for pharmaceutical companies involved in the prescription drugs market is promising, given the projected growth. Here are some key financial implications:

• Revenue Growth: Companies can expect significant revenue growth driven by the increasing demand for prescription drugs.
• Investment in R&D: Continuous investment in research and development is crucial to maintain a competitive edge and capitalize on emerging opportunities.
• Market Expansion: Expanding into new regions, particularly in the Asia Pacific, can provide additional revenue streams.
• Cost Management: Managing the high costs associated with innovative and specialty medications will be critical to maintaining profitability.

Case Study: HIV Antiretrovirals

The development and commercialization of HIV antiretrovirals, such as those involving FTC and 3TC, illustrate the potential financial and societal impact of prescription drugs. The royalty deal involving Emory University and Gilead Sciences, which resulted in a $540 million sale, highlights the significant financial rewards that can come from innovative pharmaceutical research and effective intellectual property management[2].

Key Takeaways

• The global prescription drugs market is projected to grow significantly, driven by chronic diseases, an aging population, and advances in medical research.
• North America and Europe are dominant regions, with Asia Pacific showing high growth potential.
• Online pharmacies are expected to grow rapidly due to convenience and accessibility.
• High pricing and intellectual property challenges are significant market restraints.
• Leading companies like Novartis and Pfizer maintain their position through innovation and a strong product portfolio.
• Effective regulatory oversight is crucial for market growth and public trust.

Frequently Asked Questions (FAQs)

Q: What is the projected size of the global prescription drugs market by 2032? A: The global prescription drugs market is projected to reach USD 2,151.63 billion by 2032[3].

Q: Which region dominates the global prescription drugs market? A: North America dominates the global prescription drugs market due to high healthcare expenditure and the prevalence of chronic diseases[3].

Q: What are the main drivers of the prescription drugs market? A: The main drivers include the rising prevalence of chronic diseases, a growing aging population, and advances in medical research and technology[1][4].

Q: How is the online pharmacies segment expected to grow? A: The online pharmacies segment is anticipated to grow at the highest CAGR due to the convenience and accessibility it offers to patients[3].

Q: What are the major restraints on the prescription drugs market? A: High pricing of innovative and specialty medications and intellectual property challenges are significant restraints on the market[4].